Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wiersma SR, Ortega J, Sobel E, Weinberg KI . Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991; 324: 800–808.
Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990; 75: 198–202.
Mejstrikova E, Kalina T, Trka J, Stary J, Hrusak O . Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia 2005; 19: 1092–1094.
Paul SP, Taylor LS, Stansbury EK, McVicar DW . Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000; 96: 483–490.
Inukai T, Hirose K, Inaba T, Kurosawa H, Hama A, Inada H et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 2007; 21: 288–296.
Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992; 257: 531–534.
Bodger MP, Hart DN . Molecular cloning and functional analysis of the CD33 promotor. Br J Haematol 1998; 102: 986–995.
van der Velden AHJ, te Marvelde JG, Hoogeveen PG . Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197–3204.
We thank K Nakamura (Hiroshima University, Hiroshima, Japan), Y Nagatoshi (National Kyushu Cancer Center, Fukuoka, Japan), Y Ohtsuka (University of Tokyo, Tokyo, Japan), H Inada (Kurume University School of Medicine, Kurume, Japan), and K Nakamura (Teikyo University, Tokyo, Japan) for providing clinical data of cell surface antigen expression, Wyeth Research (Pearl River, NY, USA) for providing GO, F. Rauscher III (Wister Institute, PA, USA) for providing pMT-CB6+ expression vector, and Y Akahane (Scientific Coordination Group Inc., Saitama, Japan) for sterile splitting of GO.
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on the Leukemia website
About this article
Cite this article
Akahane, K., Inukai, T., Inaba, T. et al. Specific induction of CD33 expression by E2A–HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor. Leukemia 24, 865–869 (2010) doi:10.1038/leu.2010.8
Leukemia & Lymphoma (2019)
Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
Nature Genetics (2015)
Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors
A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines
American Journal of Hematology (2010)